ALDX
Another courtroom cameo
Aldeyra Therapeutics is back in the legal spotlight, and not for a fun reason. Faruqi & Faruqi says investors who bought ALDX between November 3, 2023 and March 16, 2026 have until May 29, 2026 to seek lead-plaintiff status in a federal securities class action.
What the lawsuit says
The complaint centers on reproxalap, Aldeyra’s dry-eye candidate. Plaintiffs allege the company and its executives painted a rosier picture than reality, saying the trial data were more reliable than they really were. The lawsuit claims the results were inconsistent, and that those inconsistencies made the upbeat statements misleading.
Why investors should care
This isn’t just legal paperwork collecting dust in a filing cabinet. The lawsuit hangs over the stock like a rain cloud after the FDA’s March 17 Complete Response Letter, which rejected the NDA for reproxalap and said the company didn’t provide enough well-controlled evidence that the drug actually works.
Big picture
When a biotech story goes sideways, it usually goes sideways in two places at once: the clinic and the courtroom. Aldeyra is dealing with both, which means investors now have to think about not just drug development risk, but litigation risk too. Big picture: that’s a nasty combo.